U.S. Markets closed

Weakness Seen in Kindred Biosciences (KIN): Stock Tumbles 9.0%

Zacks Equity Research

Kindred Biosciences, Inc. (KIN) saw a big move last session, as the company’s shares fell nearly 9.0% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This continues the recent downtrend for KIN, as the stock is now down more than 28.0% in the past one-month time frame.

This slump shouldn’t be too much of a surprise to investors, as the company has seen 1 negative revision in the past few weeks and its current year earnings consensus has moved lower over the last 30 days. This suggests there may be more trouble down the road. So make sure to keep an eye on this stock going forward to see if this recent slump will continue, as the earnings picture definitely suggests that this might be the case.

KIN currently has a Zacks Rank #3 (Hold) while its Earnings ESP is negative.

Some better-ranked stocks in the healthcare sector include Actelion Ltd. (ALIOF), Alexion Pharmaceuticals, Inc. (ALXN) and Alkermes plc (ALKS). All these stocks carry a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

KINDRED BIOSCIENCES INC (KIN): Free Stock Analysis Report

ACTELION LTD (ALIOF): Free Stock Analysis Report


ALKERMES PLC ORD (ALKS): Free Stock Analysis Report

Zacks Investment Research